Approved Use

KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS® is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, or isatuximab plus dexamethasone, which are other medicines used to treat multiple myeloma.
This site is intended for U.S. residents only.

The information provided in this section is intended expressly for healthcare professionals in the United States. Click “Yes, I am” to enter if you are a U.S. healthcare professional.

Frequently Asked Questions

Here you can find answers to some frequently asked questions about KYPROLIS®. Ask your doctor if KYPROLIS® is right for you.

Is financial assistance available to help with KYPROLIS® co-pays?

We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of your current financial situation or the type of insurance you have.

If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible for co-pay programs that can help lower the out-of-pocket costs of your prescription.

Amgen® SupportPlus Co-Pay Program

AMGEN® SupportPlus co-pay card AMGEN® SupportPlus co-pay card

The Amgen SupportPlus Co-Pay Program may help patients with private or commercial insurance lower their out-of-pocket costs.

  • Pay as little as $0* out-of-pocket for each dose
  • Can be applied to deductible, co-insurance, and co-payment*
  • No income eligibility requirement

Learn more about the ways Amgen SupportPlus can help you access your prescribed medication. Visit AmgenSupportPlus.com/copay to learn more.

*Eligibility criteria and program maximums apply. See www.AmgenSupportPlus.com/copay for full Terms and Conditions.

 Can individuals without private or commercial insurance get financial assistance?

Amgen SupportPlus can provide information about independent nonprofit foundations that may be able to help.*

Call Amgen SupportPlus at (866) 264-2778, Monday–Friday 8:30 AM–8:00 PM ET, to learn more.

*Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.

 What are some important questions to discuss with my doctor?

Here are some questions to ask your doctor:

  • How long should treatment be continued for relapsed or refractory multiple myeloma patients?
  • What are the risks associated with stopping treatment for relapsed or refractory multiple myeloma?
  • How will I know that my KYPROLIS® treatment is working?
  • What are possible side effects of KYPROLIS® treatment and what are tips for managing them?
 What condition does KYPROLIS® treat?

KYPROLIS® is a treatment for adults with relapsed multiple myeloma (multiple myeloma that has returned) or refractory multiple myeloma (multiple myeloma that no longer responds to treatment). It is prescribed in combination with other medicines or alone. You and your doctor will decide which is right for you.

 How much experience does KYPROLIS® have in the treatment of relapsed or refractory multiple myeloma?

KYPROLIS® is a standard of care* for relapsed or refractory multiple myeloma with over 12 years of clinical experience.

Over 190,000 people in the United States and over 400,000 people worldwide have received KYPROLIS® treatment for their relapsed or refractory multiple myeloma since its approval.†

*A treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals. Also called best practice, standard medical care, and standard therapy.

†Total KYPROLIS® units (vials) distributed through December 2024 were obtained from the Amgen Finance Electronic Database Warehouse. An estimated total of 191,189 people in the US and 407,630 people worldwide were exposed to KYPROLIS® from launch (July 2012) through December 31, 2024 based on the latest Postmarketing Exposure Estimation report dated January 2025.

 How does KYPROLIS® work?

KYPROLIS® works in your body by inhibiting, or blocking, myeloma cell proteasomes. This is important because myeloma cells depend on proteasomes to recycle proteins in order to grow and multiply. By blocking proteasomes, KYPROLIS® causes many proteins to build up inside the cells. This way KYPROLIS® results in the death of myeloma cells.

Though KYPROLIS® affects myeloma cells more than normal cells in your body, normal cells may also be affected by treatment.

 How is KYPROLIS® treatment administered?

KYPROLIS® is given as an intravenous (IV) infusion. This is a way to put fluids, including medicine, into your bloodstream through a vein in your body. Your infusion time will range from 10 to 30 minutes depending on your treatment regimen.

 How often will I get KYPROLIS® treatment?

Depending on the combination, you will receive KYPROLIS® infusions once per week or 2 back-to-back days per week. You and your doctor will decide which dosing option works best for you. A KYPROLIS® treatment cycle typically consists of 3 weeks on and 1 week off.

 How can I make my KYPROLIS® infusion experience better?

Consider these tips to help you practice good self-care both before and after infusions.

Before your infusion:

  • Take it easy and rest
  • Drink water as instructed by your doctors
  • Dress comfortably
  • Pack a bag with snacks and something to pass the time

After your infusion:

  • Rest and recover
  • Follow any special instructions given by your health care team
 How effective is KYPROLIS® treatment for relapsed or refractory multiple myeloma?

KYPROLIS® works hard to get you through relapse. KYPROLIS® offers 4 different combination treatment regimens. You will work with your doctor to decide which is right for you.

All 4 KYPROLIS® combinations have been proven in clinical studies. The clinical studies evaluated response to treatment and median progression-free survival (the length of time from the start of treatment until half of the people in the clinical study had experienced disease progression or death). Read more about results of each KYPROLIS® combination below.

KYPROLIS® + Darzalex®* + dexamethasone†

Over 8 out of 10 people responded to KYPROLIS® + Darzalex® + dexamethasone.‡

kdd_graphic_8_10_patients-svg 2 kdd_graphic_8_10_patients-svg 2

Patients treated with KYPROLIS® + Darzalex® + dexamethasone had a median progression-free survival of 28.6 months vs 15.2 months with Kd alone (84% vs 75% with Kd alone).§

*Darzalex® (daratumumab).

†In a clinical study of 466 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 312 patients received KYPROLIS® in combination with Darzalex® and dexamethasone, and 154 received KYPROLIS® in combination with dexamethasone. The study compared how long patients lived without their disease getting worse. The median follow-up was nearly 28 months.

‡Response was defined as partial response or better.

§In an earlier analysis with a median follow-up of nearly 17 months, the median progression-free survival had not been reached with KYPROLIS® + Darzalex® + dexamethasone vs 15.8 months with Kd alone.

Kd=KYPROLIS® + dexamethasone.

KYPROLIS® + Sarclisa®* + dexamethasone†

Almost 9 out of 10 people responded to KYPROLIS® + Sarclisa® + dexamethasone (87% vs 84% with Kd alone).*,‡

9 out of 10 people 9 out of 10 people

Patients treated with KYPROLIS® + Sarclisa® + dexamethasone had a median progression-free survival of 41.7 months vs 20.8 months with Kd alone.§,**

*Sarclisa® (isatuximab-irfc).

†In a clinical study of 302 people with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 179 people received KYPROLIS® in combination with Sarclisa® and dexamethasone, and 123 received KYPROLIS® in combination with dexamethasone. The study compared how long people lived without their disease getting worse. The median follow-up was 44 months.

‡Response was defined as partial response or better.

§In an earlier analysis with a median follow-up of 21 months, the median progression-free survival had not been reached with KYPROLIS® + Sarclisa® + dexamethasone vs 20.3 months with Kd alone.

**The analysis did not include events occurring > 8 weeks from the last day of disease assessment.

Kd=KYPROLIS® + dexamethasone.

KYPROLIS® + Revlimid®* + dexamethasone†

Almost 9 out of 10 people responded to KYPROLIS® + Revlimid® + dexamethasone (87% vs 67% with Rd alone).*,‡

9 out of 10 people 9 out of 10 people

Patients treated with KYPROLIS® + Revlimid® + dexamethasone had a median progression-free survival of 26.3 months vs 17.6 months with Rd alone.

*Revlimid® (lenalidomide).

†In a clinical study of 792 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 396 patients received KYPROLIS® in combination with Revlimid® and dexamethasone, and 396 received Revlimid® in combination with dexamethasone. The study compared how long patients lived without their disease getting worse as well as how long they lived overall.

‡Response was defined as partial response or better.

Rd=Revlimid® + dexamethasone.

Once-weekly KYPROLIS® + dexamethasone

Over 6 out of 10 people responded to once-weekly KYPROLIS® + dexamethasone (62.9% with once-weekly vs 40.8% with twice-weekly Kd).*,†

6 out of 10 people 6 out of 10 people

Patients treated with once-weekly KYPROLIS® + dexamethasone had a median progression-free survival of 11.2 months vs 7.6 months with twice-weekly KYPROLIS® + dexamethasone.

*In a clinical study of 478 patients with relapsed or refractory multiple myeloma who had received 2 to 3 prior lines of therapy, 240 patients received KYPROLIS® once weekly at 70 mg/m2 in combination with dexamethasone and 238 patients received KYPROLIS® twice weekly at 27 mg/m2 in combination with dexamethasone. The study compared how long patients lived without their disease getting worse.

†Response was defined as partial response or better.

27 mg/m2 is not an FDA-approved dose for KYPROLIS® in combination with dexamethasone alone.

Twice-weekly KYPROLIS® + dexamethasone*

Almost 8 out of 10 people responded to twice-weekly KYPROLIS® + dexamethasone (77% vs 63% with Velcade® + d [Vd]).*,†

8 out of 10 people 8 out of 10 people

Patients treated with twice-weekly KYPROLIS® + dexamethasone had a median progression-free survival of 18.7 months vs 9.4 months with Vd.

*In a clinical study of 929 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 464 patients received KYPROLIS® in combination with dexamethasone, and 465 received Velcade® (bortezomib) in combination with dexamethasone. The study compared how long patients lived without their disease getting worse as well as how long they lived overall.

†Response was defined as partial response or better.

Vd=Velcade® + dexamethasone.
Access KYPROLIS® patient resources

IMPORTANT SAFETY INFORMATION

KYPROLIS® (carfilzomib) can cause serious side effects:

  • Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
  • Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
  • Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
  • Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
  • Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
  • Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
  • High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
  • Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
  • If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
  • If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone, with lenalidomide plus dexamethasone, or with daratumumab and dexamethasone.
  • Infusion-related reactions: Signs and symptoms of infusion-related reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, swelling of the larynx (voice box), vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
  • Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
  • Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
  • Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
  • Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
  • Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
  • Cases of a brain infection called Progressive Multifocal Leukoencephalopathy (PML), including fatal cases, have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms.
  • KYPROLIS should not be combined with melphalan and prednisone: Newly diagnosed transplant ineligible multiple myeloma patients have shown an increased risk of serious and fatal side effects when using KYPROLIS in combination with melphalan and prednisone.
  • Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should use effective contraception during treatment with KYPROLIS and for 6 months following the final dose. Men should use effective contraception during treatment with KYPROLIS and for 3 months following the final dose. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
  • Shortness of breath
  • Prolonged, unusual or excessive bleeding
  • Yellowing of the skin and/or eyes (jaundice)
  • Headaches, confusion, seizures, or loss of sight
  • Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
  • Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, diarrhea, high blood pressure (hypertension), tiredness (fatigue), upper airway (respiratory tract) infection, low platelets, fever, cough, difficulty breathing and sleeplessness (insomnia).

These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088

APPROVED USE

  • KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, or isatuximab plus dexamethasone, which are other medicines used to treat multiple myeloma.